 CORALVILLE, IowaBUSINESS WIREViewpoint Molecular Targeting, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced the first dosing of two neuroendocrine tumor patients with therapeutic intent. VMT-α-NET, which is being developed for the treatment and diagnosis of somatostatin receptor subtype 2 SSTR2 expressing neuroendocrine tumors, was administered to the patients ...... 